--- title: "AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day" type: "News" locale: "en" url: "https://longbridge.com/en/news/275174622.md" description: "AbbVie Inc. (ABBV) shares rose 2.01% to $223.43 on a strong trading day, outperforming some competitors. The S&P 500 Index increased by 1.97%, while the Dow Jones Industrial Average rose by 2.47%. AbbVie is 8.73% below its 52-week high of $244.81. Competitors like Johnson & Johnson, Pfizer, and Amgen also saw gains, with Amgen leading at 4.49%. Trading volume was below the 50-day average." datetime: "2026-02-06T21:32:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275174622.md) - [en](https://longbridge.com/en/news/275174622.md) - [zh-HK](https://longbridge.com/zh-HK/news/275174622.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275174622.md) | [繁體中文](https://longbridge.com/zh-HK/news/275174622.md) # AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) advanced 2.01% to $223.43 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 1.97% to 6,932.30 and the Dow Jones Industrial Average rising 2.47% to 50,115.67. This was the stock's second consecutive day of gains. AbbVie Inc. closed 8.73% short of its 52-week high of $244.81, which the company reached on October 1st. The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) rose 0.93% to $239.99, Pfizer Inc. (PFE) rose 2.76% to $27.22, and Amgen Inc. (AMGN) rose 4.49% to $384.32. Trading volume (6.0 M) remained 431,507 below its 50-day average volume of 6.5 M. Data source: Dow Jones Market Data, FactSet. Data compiled February 6, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 02-06-26 1632ET ### Related Stocks - [Amgen Inc. (AMGN.US)](https://longbridge.com/en/quote/AMGN.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [AbbVie Inc. (ABBV.US)](https://longbridge.com/en/quote/ABBV.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md) - [S&P 500 (.SPX.US)](https://longbridge.com/en/quote/.SPX.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Pfizer Inc. (PFE.US)](https://longbridge.com/en/quote/PFE.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU.US)](https://longbridge.com/en/quote/TBXU.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [Johnson & Johnson (JNJ.US)](https://longbridge.com/en/quote/JNJ.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) ## Related News & Research - [Richard Bernstein Advisors LLC Lowers Holdings in AbbVie Inc. $ABBV](https://longbridge.com/en/news/278554123.md) - [AbbVie reports topline data from Phase I ABBV-295 trial](https://longbridge.com/en/news/278540526.md) - [AbbVie's Early Obesity Drug Data Shows Up To 10% Weight Loss](https://longbridge.com/en/news/278409007.md) - [Forecasting The Future: 15 Analyst Projections For Amgen](https://longbridge.com/en/news/278570699.md) - [AbbVie's ABBV-295 Shows Strong Weight Loss Results in Phase 1 Trial](https://longbridge.com/en/news/278398258.md)